Westover Capital Advisors LLC Has $513,000 Holdings in Boston Scientific Corporation $BSX

Westover Capital Advisors LLC cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 66.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,375 shares of the medical equipment provider’s stock after selling 10,486 shares during the period. Westover Capital Advisors LLC’s holdings in Boston Scientific were worth $513,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Murphy & Mullick Capital Management Corp lifted its position in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter worth about $26,000. United Community Bank boosted its holdings in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares during the last quarter. Colonial Trust Co SC boosted its holdings in Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares during the last quarter. Finally, Bangor Savings Bank boosted its holdings in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director directly owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 9,800 shares of company stock worth $554,012 in the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 0.1%

NYSE:BSX opened at $57.71 on Monday. Boston Scientific Corporation has a fifty-two week low of $52.52 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market capitalization of $85.77 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 1.06 and a beta of 0.62. The business’s 50-day simple moving average is $61.97 and its 200-day simple moving average is $80.12.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the business posted $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on BSX shares. The Goldman Sachs Group reduced their target price on Boston Scientific from $87.00 to $84.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Needham & Company LLC restated a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a report on Monday, May 18th. Barclays reduced their target price on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a report on Thursday, April 23rd. Argus upgraded Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Finally, BTIG Research restated a “buy” rating and set a $80.00 target price on shares of Boston Scientific in a report on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Several Boston Scientific directors bought shares this week, including Cheryl Pegus, David C. Habiger, and Edward J. Ludwig. Heavy insider buying often signals management confidence and can help support sentiment around BSX. Article Title
• Positive Sentiment: Boston Scientific’s board authorized a $5 billion share repurchase program, which can be viewed as a sign that management believes the stock may be undervalued and could provide downside support. Article Title
• Positive Sentiment: Boston Scientific recently reported earnings and revenue that slightly beat expectations and raised guidance for 2026, reinforcing the company’s longer-term growth story even though the stock has remained weak.
• Neutral Sentiment: Recent analyst commentary has been mixed: firms like Baird and Stifel still have positive ratings, but several price targets were trimmed, suggesting Wall Street remains constructive while tempering expectations. Article Title
• Negative Sentiment: Coverage asking why BSX is down 13% since its last earnings report highlights lingering investor concern that the stock has not kept pace with its fundamentals, likely weighing on near-term trading. Article Title

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.